Taljat David / Shutterstock.com
Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya (fingolimod) is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at email@example.com
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, Gilenya, Judge Maryellen Noreika, US District Court for the District of Delaware, Handa Pharmaceuticals